HIF Stabilizer Desidustat Protects against Complement-Mediated Diseases
Drug Research · 01.09.2024 · 74 (07) · 325-334
DOI: 10.1055/a-2347-9919 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Research, erschienen am 01.09.2024. Verfasst von Vishal J Patel und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Toxicology, Zydus Research Centre, Zydus Lifesciences Limited, Moraiya, Ahmedabad, India. Hauptthemen laut MEDLINE: Complement Activation. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 35 Literaturangaben.
Abstract (Originalsprache)
Complement cascade is a defence mechanism useful for eliminating pathogenic microorganisms and damaged cells. However, activation of alternative complement system can also cause inflammation and promote kidney and retinal disease progression. Inflammation causes tissue hypoxia, which induces hypoxia-inducible factor (HIF) and HIF helps the body to adapt to inflammation. In this study, we investigated the effect of HIF stabilizer desidustat in complement-mediated diseases. Oral administration of desidustat (15 mg/kg) was effective to reduce the kidney injury in mice that was induced by either lipopolysaccharide (LPS), doxorubicin or bovine serum albumin (BSA)-overload. Complement activation-induced membrane attack complex (MAC) formation and factor B activity were also reduced by desidustat treatment. In addition, desidustat was effective against membranous nephropathy caused by cationic BSA and retinal degeneration induced by sodium iodate in mice. C3-deposition, proteinuria, malondialdehyde, and interleukin-1ß were decreased and superoxide dismutase was increased by desidustat treatment in cBSA-induced membranous nephropathy. Desidustat specifically inhibited alternative complement system, without affecting the lectin-, or classical complement pathway. This effect appears to be mediated by inhibition of factor B. These data demonstrate the potential therapeutic value of HIF stabilization by desidustat in treatment of complement-mediated diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology and Toxicology, Zydus Research Centre, Zydus Lifesciences Limited, Moraiya, Ahmedabad, India.
ORCID-Profile: Amit A Joharapurkar
Zitieren
APA
Patel, V. J., Joharapurkar, A. A., Kshirsagar, S. G., Patel, M. S., Savsani, H. H., Dodiya, H. S., Rakhasiya, M. H., Patel, A. K., Sundar, R., & Jain, M. R. (2024). HIF Stabilizer Desidustat Protects against Complement-Mediated Diseases. Drug Research, 74(07), 325-334. https://doi.org/10.1055/a-2347-9919
Vancouver
Patel VJ, Joharapurkar AA, Kshirsagar SG, Patel MS, Savsani HH, Dodiya HS, et al. HIF Stabilizer Desidustat Protects against Complement-Mediated Diseases. Drug Research. 2024;74(07):325-334. doi:10.1055/a-2347-9919
BibTeX
@article{Patel2024,
author = {Patel, Vishal J and Joharapurkar, Amit A and Kshirsagar, Samadhan G and Patel, Maulik S and Savsani, Hardikkumar H and Dodiya, Harshad S and Rakhasiya, Milan H and Patel, Ashvin K and Sundar, Rajesh and Jain, Mukul R},
title = {HIF Stabilizer Desidustat Protects against Complement-Mediated Diseases},
journal = {Drug Research},
year = {2024},
volume = {74},
number = {07},
pages = {325--334},
doi = {10.1055/a-2347-9919}
}
EUVIMED